Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 5567 Download: 198 Crossref: 1

Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease

Andrea Caddeo, Stefano Romeo

Clin Mol Hepatol. 2025;31(Suppl):S76-S93. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0438

View: 2464 Download: 405 Crossref: 7

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia

Clin Mol Hepatol. 2025;31(Suppl):S285-S300. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0323

View: 1316 Download: 158 Crossref: 1

Epidemiology of metabolic dysfunction-associated steatotic liver disease

Zobair M. Younossi, Markos Kalligeros, Linda Henry

Clin Mol Hepatol. 2025;31(Suppl):S32-S50. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0431

View: 7244 Download: 1,605 Crossref: 19

Alcohol-associated liver disease: Natural history, management and novel targeted therapies

Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós-Ginès, Ana Clemente-Sánchez, Hugo López-Pelayo, Ramón Bataller

Clin Mol Hepatol. 2025;31(Suppl):S112-S133. Published online October 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0709

View: 1515 Download: 228 Crossref: 2

Hepatitis E as a trigger for acute-on-chronic liver failure

Maria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, Mar Riveiro-Barciela

Clin Mol Hepatol. 2025;31(Suppl):S196-S204. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0758

View: 1071 Download: 121

Prospect of emerging treatments for hepatitis B virus functional cure

Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(Suppl):S165-181. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0855

View: 1559 Download: 307 Crossref: 4

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 1235 Download: 134 Crossref: 1

Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications

Jaeho Park, Yi-Te Lee, Vatche G. Agopian, Jessica S Liu, Ekaterina K. Koltsova, Sungyong You, Yazhen Zhu, Hsian-Rong Tseng, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S255-S284. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0541

View: 1223 Download: 159

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 3083 Download: 281 Crossref: 3

Prediction and management of small-for-size syndrome in living donor liver transplantation

Jia-hao Law, Alfred Wei-Chieh Kow

Clin Mol Hepatol. 2025;31(Suppl):S301-S326. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0870

View: 591 Download: 79

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S228-S254. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0824

View: 3023 Download: 587 Crossref: 2

Liver organoids: Current advances and future applications for hepatology

Yohan Kim, Minseok Kang, Michael Girma Mamo, Michael Adisasmita, Meritxell Huch, Dongho Choi

Clin Mol Hepatol. 2025;31(Suppl):S327-S348. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1040

View: 1363 Download: 215

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-sheng Wang, Man-Fung Yuen, Qin Ning

Clin Mol Hepatol. 2025;31(Suppl):S134-S164. Published online January 22, 2025

DOI: https://doi.org/10.3350/cmh.2024.0780

View: 1698 Download: 298

Prediction and prevention of post-procedural bleedings in patients with cirrhosis

Alix Riescher-Tuczkiewicz, Pierre-Emmanuel Rautou

Clin Mol Hepatol. 2025;31(Suppl):S205-S227. Published online February 18, 2025

DOI: https://doi.org/10.3350/cmh.2024.0928

View: 979 Download: 123

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 542 Download: 89

Snapshot

Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues

Clara Meda, Arianna Dolce, Sara Della Torre

Clin Mol Hepatol. 2025;31(1):327-332. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0419

View: 901 Download: 78

Editorial

Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”

Sergi Marco, Chiara Braconi

Clin Mol Hepatol. 2025;31(1):323-326. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0932

View: 670 Download: 34 Crossref: 1

Understanding the impact on digestive disease in the post-COVID-19 condition: Editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK”

Yang-Hyun Baek

Clin Mol Hepatol. 2025;31(1):319-322. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0856

View: 728 Download: 28 Crossref: 2

The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study”

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2025;31(1):316-318. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0847

View: 768 Download: 51

Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Naoshi Nishida

Clin Mol Hepatol. 2025;31(1):311-315. Published online September 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0739

View: 856 Download: 64 Crossref: 2

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):308-310. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0726

View: 932 Download: 70 Crossref: 1

Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”

Rainbow Wing Hei Leung, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(1):304-307. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0718

View: 853 Download: 47 Crossref: 1

Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):301-303. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0716

View: 879 Download: 70 Crossref: 1

A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Johanna K. DiStefano, Glenn S. Gerhard

Clin Mol Hepatol. 2025;31(1):297-300. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0704

View: 805 Download: 30 Crossref: 1

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Andrea Caddeo, Rosellina M. Mancina

Clin Mol Hepatol. 2025;31(1):293-296. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0703

View: 1028 Download: 101 Crossref: 2

MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Rex Wan-Hin Hui, Lung-Yi Mak

Clin Mol Hepatol. 2025;31(1):290-292. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0630

View: 804 Download: 26 Crossref: 1

From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023”

Ilona Argirion

Clin Mol Hepatol. 2025;31(1):286-289. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0597

View: 782 Download: 29

UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma: Editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”

Martina Mang Leng Lei, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(1):281-285. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0568

View: 1269 Download: 77 Crossref: 2

Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Won Sohn

Clin Mol Hepatol. 2025;31(1):277-280. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0823

View: 937 Download: 33 Crossref: 1

Viewed By 6974	MAFLD: How is it different from NAFLD?
Viewed By 6225	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5317	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5150	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4664	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 266	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 170	MAFLD: How is it different from NAFLD?
Cited By 92	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Topics